Kenneth Galbraith
Known title: Chair & CEOCIK: 0001567045
Associated companies
Transaction History
| ZYME | ▲ Buy | Option Exercise | 64,000 | $0 | 1/12/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 30,424 | $690K | 1/12/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 22,657 | $569K | 1/5/2026 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 66,666 | $0 | 1/5/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 31,686 | $795K | 1/5/2026 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 47,668 | $0 | 1/5/2026 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 100,000 | $0 | 12/22/2025 | View on chart |
| ZYME | ▼ Sell | Open Market | 47,528 | $1.3M | 12/22/2025 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 47,666 | $0 | 1/6/2025 | View on chart |
| ZYME | ▼ Sell | Open Market | 23,885 | $356K | 1/6/2025 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 66,666 | $0 | 1/6/2025 | View on chart |
| ZYME | ▼ Sell | Open Market | 33,406 | $499K | 1/6/2025 | View on chart |
| ZYME | ▼ Sell | Open Market | 5,706 | $64K | 1/8/2024 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 47,666 | $0 | 1/5/2024 | View on chart |
| ZYME | ▼ Sell | Open Market | 18,198 | $194K | 1/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZYME News Highlights Potential Undervaluation and Raised Price Target
Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.
ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.